Research Brief: How to Build Medical Device Software with AI (Compliance, Architecture, and Development Process)

Source URL: https://geekyants.com/en-us/blog/how-to-build-medical-device-software-with-ai-compliance-architecture-and-development-process

Publisher: GeekyAnts (July 24, 2026)

Authors/SMEs: Sathavalli Yamini, Manav Goel (Principal Technical Consultant), Saurabh Sahu (CTO), Kunal Kumar (CRO)

Target Audience: VPs of Engineering, Platform Leaders, Digital Product Leaders in Healthcare and MedTech

Saved Location: `./workspace/

1. Executive Summary & Market Drivers

• Market Shift: AI-enabled medical devices grew past $13B in 2024 and are projected to surpass $250B by 2033 (38.5% CAGR). Healthcare organization genAI adoption jumped from 25% (late 2023) to 50% (2026).
• Procurement Dynamic: RFPs have shifted from feature lists to compliance timelines. Quality/compliance leads evaluate IEC 62304 experience and submission histories before technical CTO calls take place.
• Core Rule: Standard software tolerates retrospective documentation and iterative trial; medical device software treats unrecorded design decisions as audit gaps and skipped early validation as mandatory full redesigns at submission.

2. Core Challenges & AI vs. Standard SaMD

Challenges in Medical Device Software

1. Regulatory Traceability: Requirements, risk management, and testing across firmware, cloud, and EHR must maintain end-to-end bi-directional traceability.

2. Change Control Collision: Code edits require risk assessment, regression testing, and potential regulatory notifications—colliding with fast consumer Agile deployments.

3. Interoperability & Clinical Risk: Incomplete or malformed EHR data fed into clinical algorithms creates direct clinical safety risks.

4. Hardware/Software Lifecycle Desynchronization: Regulated system classifications cover whole devices; software waiting on hardware (or vice versa) creates expensive certification stalls.

Differences: AI Software vs. Standard SaMD

• Data Provenance: Training datasets require strict lineage, uniform labeling standards, and total separation from validation sets.
• Model Governance & Subgroup Bias: Performance metrics must be defined pre-deployment and benchmarked across demographic/clinical subgroups.
• Explainability & Clinician Guardrails: Confidence scores, interpretability outputs, and explicit Human-in-the-Loop (HITL) review loops are mandatory for high-risk decisions.
• Locked vs. Adaptive Models: Locked models freeze after clearance. Adaptive/learning models require a Predetermined Change Control Plan (PCCP), drift monitoring, and pre-approved retraining triggers on file with regulators.

3. The 7-Layer Architecture Framework

A production-ready clinical-grade AI SaMD system requires seven distinct layers connected by explicit data contracts:

1. Device and Edge Layer: Wearables, sensors, connected hardware. Manages low-latency data capture at source to prevent downstream signal corruption.

2. Data Ingestion Layer: HL7 and FHIR APIs. Ingests EHR, lab, and imaging data with validated provenance and schema compliance.

3. Cloud and Backend Layer: Scalable infrastructure handling authentication, audit logs, database transactions, and uptime under peak hospital loads.

4. AI/ML Model Layer: Diagnostic algorithms, predictive models, and decision support engines. Manages inference, confidence scores, PCCP triggers, and audit trails.

5. Clinical Application Layer: Interfaces for clinicians/patients. Subject to ISO 62366 usability validation where every interaction shaping clinical decisions carries documented risk.

6. Security and Compliance Layer: Pre-market FDA cybersecurity controls, threat modeling, Software Bill of Materials (SBOM), role-based access control (RBAC), and encryption (in transit and at rest).

7. Monitoring and Observability Layer: Post-market tracking of data quality, model drift, system uptime, and performance degradation feeding post-market surveillance (PMS) obligations.

4. Lifecycle & Development Process

| Phase | Core Actions | Required Regulatory Evidence / Artifacts |

|---|---|---|

| Discovery | Intended use definition, risk classification, clinician workflow mapping, AI vs. rule-based boundaries | Intended Use Statement, Initial Risk File (ISO 14971) |

| Architecture | Data flow mapping, API design, security controls, risk classification verification | Architecture Diagram, Data Flow Map, Cybersecurity Threat Model |

| Prototype | Core ingestion proof, basic inference proof, clinician interface feedback | Prototype Test Results, Feasibility Sign-off |

| Verification & Validation (V&V) | Clinical condition testing, edge case simulation, interoperability, security penetration tests | Verification/Validation Test Reports, Traceability Matrix |

| Launch / Release | Controlled deployment, release controls, audit trail locking | Deployment Records, Post-Market Monitoring Plan, PCCP |

• Agile Integration: Agile sprints suit Discovery, Prototyping, and UX iteration. V&V and formal submissions require fixed gates and continuous evidence generation during every sprint.

5. Regulatory, Standards, & Security Spectrum

• FDA Pathways (US): 510(k) for low/medium risk with predicate; De Novo or Premarket Approval (PMA) for novel/higher risk.
• EU MDR (Europe): CE marking with stringent Post-Market Clinical Follow-up (PMCF) obligations.
• Standards Stack:

* ISO 13485: Quality Management System (QMS) for medical devices.

* IEC 62304: Software lifecycle processes (architecture, coding standards, verification, maintenance).

* ISO 14971: Application of risk management to medical devices.

* IEC 62366: Application of usability engineering to medical devices.

• Cybersecurity & Data Privacy:

* FDA Premarket Cybersecurity Guidance: Demands SBOM, threat modeling, vulnerability handling, and patch management.

* Privacy: HIPAA (US) and GDPR (EU) compliance for PHI/PII handling.

6. Failure Modes and Mitigation Strategies

1. Failure Mode: Locking architecture before confirming IEC 62304 risk class.

Mitigation:* Perform formal risk classification during Discovery before locking system architecture.

2. Failure Mode: Assembling the Requirements Traceability Matrix post-hoc.

Mitigation:* Maintain a live bi-directional matrix linking every requirement to design specs and automated test cases from Sprint 1.

3. Failure Mode: Treating security, threat modeling, and SBOM as pre-launch cleanup.

Mitigation:* Integrate security testing, dependency vulnerability scans, and SBOM generation directly into CI/CD build pipelines.

4. Failure Mode: Rushing HL7/FHIR EHR data integration.

Mitigation:* Validate integration schemas early; treat data pipelines with the same engineering rigor as core ML algorithms.

5. Failure Mode: Treating software launch as a one-time static delivery.

Mitigation:* Plan post-market surveillance, drift monitoring, retraining triggers, and maintenance budgets from inception.

7. Partner Evaluation Criteria

Organizations choosing vendor or consulting support for AI SaMD builds require:

• Proven submission history with FDA 510(k)/De Novo and EU MDR clearances.
• Engineers trained to use IEC 62304, ISO 13485, and ISO 14971 as active design inputs.
• Production experience with HL7/FHIR interoperability under hospital loads.
• Continuous security engineering (SBOM, threat modeling) embedded in development sprints.
• Support models extending into post-market surveillance, continuous monitoring, and PCCP execution.